Evaluation of innate lymphoid cells and their subsets in atopic dermatitis patients with and without dupilumab therapy
2024
Abstract
The aim of the study is to evaluate the count of innate lymphoid cells (ILCs) and their types (ILC -1, ILC-2, ILC-3, ILC-3 NCR+, ILC-3 NCR-) in atopic dermatitis (AD) patients with and without dupilumab therapy and evaluate the relation to the severity of atopic dermatitis. In AD patients without dupilumab therapy, we confirmed the significantly lower count of total ILCs, ILC-2 and ILC-3 NCR-.
The relation between the severity of AD and the count of ILC cells and their subsets was not confirmed. Our results suggest that dupilumab affects the count of ILC cells.
Dupilumab normalizes the level of ILC cells in peripheral blood (total, ILC- 2 and ILC-3 NCR-).